Alnylam Pharmaceuticals, Inc. share price logo

Alnylam Pharmaceuticals, Inc. Share Price

NASDAQ: ALNY

Large Cap

$451.23

-10.01

(-2.17%)

as on

Alnylam Pharmaceuticals, Inc. Stock Performance

as on September 18, 2025 at 1:29 am IST

  • Day's Low

    Day's High

    $450.74
    $463.88
    downward going graph

    0.11%

    Downside

    2.80%

    Upside

    downward going graph
  • 52 Week's Low

    52 Week's High

    $205.87
    $484.21
    downward going graph

    54.38%

    Downside

    7.31%

    Upside

    downward going graph

Alnylam Pharmaceuticals, Inc. share price movements today

Previous Close
$461.24
Open
$458.68
Volume
608.5K
Day's Low - High
$450.74 - $463.88
52 Week Low - High
$205.87 - $484.21

Alnylam Pharmaceuticals, Inc. Historical Returns

1 Month Return
+ 2.75 %
3 Month Return
+ 49.41 %
1 Year Return
+ 68.05 %
3 Year Return
+ 116.54 %
5 Year Return
+ 252.04 %

Alnylam Pharmaceuticals, Inc. Stock Fundamentals & Key Indicators

Check Alnylam Pharmaceuticals, Inc. market cap, PE, PB, PEG ratios, dividend yield, and other key fundamental indicators.

Market Cap

$60.5B

EPS (TTM)

3.8648

Dividend Yield

0.00%

Quarterly Earnings Growth YOY

0.00%

PE Ratio (TTM)

-505.15

Industry PE ratio

15.754285714285714

P/B Ratio

0

PEG Ratio

-0.49

EBITDA

-123.7M

Revenue (TTM)

2.5B

Profit Margin

-12.96%

Return On Equity TTM

576368800.00%

Alnylam Pharmaceuticals, Inc. Stock Valuation

Track how Alnylam Pharmaceuticals, Inc. P/E has moved over time to understand its valuation trends.

Alnylam Pharmaceuticals, Inc. in the last 5 years

  • Overview

  • Trends

Lowest (0.00x)

September 17, 2025

Today (-505.15x)

September 17, 2025

Industry (15.75x)

September 17, 2025

Highest (0.00x)

September 17, 2025

LowHigh

Today’s Price to Earnings Ratio: -505.15x

Alnylam Pharmaceuticals, Inc. vs Peer Comparison

Compare market cap, revenue, PE, and other key metrics of Alnylam Pharmaceuticals, Inc. with its industry peers.

Company
Analyst View
Market Cap
5 Years Return %PE RatioProfit Margin %
BUY$60.5B252.04%-505.15-12.96%
NA$39.0BNANA-3.89%
BUY$100.3B44.17%27.8531.86%
BUY$59.6B1.78%14.131.37%

Stock Returns calculator for Alnylam Pharmaceuticals, Inc. Stock including INR - Dollar returns

The Alnylam Pharmaceuticals, Inc. stock calculator helps Indian investors calculate returns based on the historical performance of the stock. Just choose your investment amount and duration to get insights and invest more confidently. See stock returns as well as the effect of dollar appreciation over different durations.

*Dollar Return is the profit earned when the US dollar rises in value compared to the Indian rupee.

Investment Value

₹1,00,000

  • 1Y

  • 3Y

  • 5Y

  • 7Y

  • 10Y

Alnylam Pharmaceuticals, Inc. investment value today

Current value as on today

₹1,69,005

Returns

₹69,005

(+69%)

Returns from Alnylam Pharmaceuticals, Inc. Stock

₹64,406 (+64.41%)

Dollar Returns*

₹4,598 (+4.6%)

Analyst Recommendation on Alnylam Pharmaceuticals, Inc. Stock

Based on 34 analysts

BUY

70.59%

Buy

29.41%

Hold

0.00%

Sell

Based on 34 analysts, 70.59% of analysts recommend a 'BUY' rating for Alnylam Pharmaceuticals, Inc.. Average target price of $442.44

Alnylam Pharmaceuticals, Inc. Share Price Target

Get share price movements and forecasts by analysts on Alnylam Pharmaceuticals, Inc..

What analysts predicted

-1.99%DOWNSIDE

Target Price

$442.44

Current Price

$451.23

Analyzed by

34 Analysts

Target

$442.44

Alnylam Pharmaceuticals, Inc. target price $442.44, a slight downside of -1.99% compared to current price of $451.23. According to 34 analysts rating.

Alnylam Pharmaceuticals, Inc. Stock's Interest Amongst Investors

Investment in Alnylam Pharmaceuticals, Inc. Shares on INDmoney has grown by 49.12% over the past 30 days, indicating increased transactional activity.

Time period: to

Change:49.12% versus previous 30 day period

Search interest for Alnylam Pharmaceuticals, Inc. Stock has increased by 122% in the last 30 days, reflecting an upward trend in search activity.

Time period: to

Change:122% versus previous 30 day period

Alnylam Pharmaceuticals, Inc. Quarterly Profit & Loss

All numbers in Millions USD

Mar 2023
Jun 2023
Sep 2023
Dec 2023
Mar 2024
Jun 2024
Sep 2024
Dec 2024
Mar 2025
Jun 2025
Total Revenue
319
318
750
439
494
659
500
593
594
773
Gross Profit
264
233
666
353
428
591
415
490
523
630
Operating Income
-149
-229
213
-116
-43
48
-76
-105
18
-16
EBITDA
-129
-230
194
-92
-14
37
-60
-140
11
18
Interest Expense
28
30
30
31
35
33
34
38
38
40
Depreciation
26
23
23
23
25
24
27
-20
14
13
Income Before Tax
-172
-274
150
-137
-63
-11
-108
-193
-41
-35
Income Tax Expense
1
1
2
0
2
5
2
-110
15
30
Net Income
-174
-276
147
-137
-65
-16
-111
-83
-57
-66
Net Profit Margin
-54.53%
-86.59%
19.69%
-31.35%
-13.34%
-2.56%
-22.27%
-14.12%
-9.67%
-8.57%

Alnylam Pharmaceuticals, Inc. Annual Profit & Loss

All numbers in Millions USD

Dec 2015
Dec 2016
Dec 2017
Dec 2018
Dec 2019
Dec 2020
Dec 2021
Dec 2022
Dec 2023
Dec 2024
Total Revenue
41
47
89
74
219
492
844
1,037
1,828
2,248
Gross Profit
41
47
89
73
194
414
704
868
1,517
1,924
Operating Income
-296
-424
-500
-814
-939
-828
-708
-785
-282
-176
EBITDA
-276
-409
-486
-754
-885
-736
-661
-926
-258
-178
Interest Expense
5
8
12
29
108
84
143
155
121
141
Depreciation
-
-
13
6
54
74
89
85
97
56
Income Before Tax
-290
-410
-490
-760
-885
-855
-852
-1,126
-433
-377
Income Tax Expense
-24
-23
-25
0
0
2
0
4
6
-99
Net Income
-290
-410
-490
-761
-886
-858
-852
-1,131
-440
-278
Net Profit Margin
-705.83%
-869.63%
-545.95%
-1016.58%
-403.24%
-174.15%
-101.01%
-109.04%
-24.08%
-12.37%

Alnylam Pharmaceuticals, Inc. Quarterly Cash Flow

All numbers in Millions USD

Jun 2023
Sep 2023
Dec 2023
Mar 2024
Jun 2024
Sep 2024
Dec 2024
Mar 2025
Jun 2025
Net Income
-276
147
-137
-65
-16
-111
-83
-57
-66
Operating Cash Flow
-58
359
-29
-81
124
43
-94
-118
153
Investing Cash Flow
-8
-10
-240
-67
33
-30
-52
113
-141
Financing Cash Flow
53
33
39
28
131
102
30
44
53
Change in Cash
-14
375
-220
-130
286
131
-133
53
93

Alnylam Pharmaceuticals, Inc. Annual Cash Flow

All numbers in Millions USD

Dec 2016
Dec 2017
Dec 2018
Dec 2019
Dec 2020
Dec 2021
Dec 2022
Dec 2023
Dec 2024
Net Income
-410
-490
-761
-886
-858
-852
-1,131
-440
-278
Operating Cash Flow
-307
-382
-562
-278
-614
-641
-541
104
-8
Investing Cash Flow
142
-290
272
-417
-435
-273
169
-336
-116
Financing Cash Flow
177
1,124
65
823
994
1,247
425
172
294
Change in Cash
12
451
-224
126
-50
323
46
-53
153

Global Institutional Holdings in Alnylam Pharmaceuticals, Inc.

Funds
Holdings
Capital World Investors
12.78%
FMR Inc
11.68%
Vanguard Group Inc
9.96%
BlackRock Inc
7.29%
Capital Research Global Investors
5.46%

Insights on Alnylam Pharmaceuticals, Inc.

Insights help you understand the recent movement of the company's critical parameters, giving you an overall view of the company.

  • imgPOSITIVE IMPACT

    Revenue Rich

    img

    Alnylam Pharmaceuticals, Inc. has experienced consistent revenue growth over the last four quarters. The revenue increased from $500.91 million to $773.68 million. This represents an average increase of 13.0% per quarter.

  • imgPOSITIVE IMPACT

    Best in 3 Years

    img

    In the last 3 years, ALNY has outperformed top 5 stocks with highest market-cap in its industry

  • imgPOSITIVE IMPACT

    Price Rise

    img

    In the last 3 months, ALNY stock has moved up by 49.4%

  • imgPOSITIVE IMPACT

    Best in 1 Year

    img

    In the last 1 year, ALNY has outperformed top 5 stocks with highest market-cap in its industry

  • imgNEGATIVE IMPACT

    Profit Down

    img

    Alnylam Pharmaceuticals, Inc. has seen a decline in its net profit over the last two quarters. The net profit decreased from -$57.47 million to -$66.27 million, which means the company is losing more money. This represents an average decrease of 15.3% in net profit each quarter.

About Alnylam Pharmaceuticals, Inc.

alnylam is developing an entirely new class of innovative medicines based on a breakthrough discovery in biology known as rna interference, or rnai. with rnai technology, we have the opportunity to treat disease and impact the lives of patients in a fundamentally new way by silencing disease-causing genes upstream of today's medicines.
OrganisationAlnylam Pharmaceuticals, Inc.
Headquarters675 West Kendall Street, Cambridge, MA, United States, 02142
IndustryHealth Technology
CEODr. Yvonne L. Greenstreet M.B.A., M.D.
E-voting on sharesClick here to vote

Key Management of Alnylam Pharmaceuticals, Inc.

Name

Title

Mr. Tolga Tanguler M.B.A.

Executive VP & Chief Commercial Officer

Ms. Christine Regan Akinc

Chief Corporate Communications Officer

Dr. Muthiah Manoharan Ph.D.

Senior VP of Innovation Chemistry & Distinguished Scientist and Member of Scientific Advisory Board

Dr. Yvonne L. Greenstreet M.B.A., M.D.

CEO & Director

Mr. Jeffrey V. Poulton M.B.A.

CFO & Executive VP

Dr. Kevin Joseph Fitzgerald Ph.D.

Executive VP, Chief Scientific Officer and Head of Early Research & Early Development

Ms. Melissa McLaughlin M.B.A.

Chief Human Resources Officer

Dr. Phillip A. Sharp Ph.D.

Co-Founder, Member of the Scientific Advisory Board

Mr. Timothy J. Maines

Chief Technical Operations & Quality Officer

Mr. Piyush Sharma J.D.

Chief Ethics & Compliance Officer

FAQs

What is Alnylam Pharmaceuticals, Inc. share price today?

Alnylam Pharmaceuticals, Inc. share price today is $451.23 as on at the close of the market. Alnylam Pharmaceuticals, Inc. share today touched a day high of $463.88 and a low of $450.74.

What is the 52 week high and 52 week low for Alnylam Pharmaceuticals, Inc. share?

Alnylam Pharmaceuticals, Inc. share touched a 52 week high of $484.21 on and a 52 week low of $205.87 on . Alnylam Pharmaceuticals, Inc. stock price today i.e. is closed at $451.23,which is 6.81% down from its 52 week high and 119.18% up from its 52 week low.

What is Alnylam Pharmaceuticals, Inc.'s market capitalisation today?

Alnylam Pharmaceuticals, Inc. market capitalisation is $0.06T as on .

How to invest in Alnylam Pharmaceuticals, Inc. Stock (ALNY) from India?

  1. Step 1: Open a free US stocks account on INDmoney App and transfer your Rupees into Dollars to your INDmoney US stocks account. For a step by step instruction, check How to Transfer Money to Your US Stocks Account .
  2. Step 2: Search for Alnylam Pharmaceuticals, Inc. on INDmoney app. Click on Buy button. You can invest as low as $1.5 in Alnylam Pharmaceuticals, Inc. Shares that will get you 0.0033 shares as per Alnylam Pharmaceuticals, Inc. share price of $451.23 per share as on September 18, 2025 at 1:29 am IST.

What is the minimum amount required to buy Alnylam Pharmaceuticals, Inc. Stock (ALNY) from India?

Indian investors can start investing in Alnylam Pharmaceuticals, Inc. (ALNY) shares with as little as ₹87.816 or $1 (as of ) using the INDmoney app.
For example: If you want to invest $10 or ₹878.16 in Alnylam Pharmaceuticals, Inc. stock (as per the Rupee-Dollar exchange rate as on ). Based on Alnylam Pharmaceuticals, Inc. share’s latest price of $451.23 as on September 18, 2025 at 1:29 am IST, you will get 0.0222 shares of Alnylam Pharmaceuticals, Inc.. Learn more about fractional shares .

What are the returns that Alnylam Pharmaceuticals, Inc. has given to Indian investors in the last 5 years?

Alnylam Pharmaceuticals, Inc. stock has given 252.04% share price returns and 20.01% dollar appreciation to an Indian investor in the last 5 years.
Read more about How do Currency Exchange Rates impact your returns on US Stock Investments?